共 16 条
[1]
Azzari C, 2016, RIAP RIV IMMUNOLOGIA, V3, P38
[4]
de Sanjose S, 2012, Vaccine, V30 Suppl 4, pD1, DOI 10.1016/S0264-410X(12)01435-1
[5]
European Medicines Agency, GARD HUM PAP VACC TY
[6]
European Medicines Agency, GARD
[7]
European Medicines Agency, CERV HUM PAP VACC TY
[9]
Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
[J].
PAPILLOMAVIRUS RESEARCH,
2015, 1
:90-100